 Infliximab
"Infliximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.
| Descriptor ID |
D000069285
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.608 D12.776.124.790.651.114.224.537 D12.776.377.715.548.114.224.642
|
| Concept/Terms |
Infliximab- Infliximab
- MAb cA2
- Monoclonal Antibody cA2
- cA2, Monoclonal Antibody
|
Below are MeSH descriptors whose meaning is more general than "Infliximab".
Below are MeSH descriptors whose meaning is more specific than "Infliximab".
This graph shows the total number of publications written about "Infliximab" by people in this website by year, and whether "Infliximab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 3 | 3 | | 2001 | 0 | 4 | 4 | | 2002 | 0 | 3 | 3 | | 2003 | 0 | 2 | 2 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 5 | 5 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 6 | 6 | | 2012 | 0 | 3 | 3 | | 2013 | 0 | 4 | 4 | | 2014 | 2 | 4 | 6 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 2 | 2 | | 2017 | 1 | 1 | 2 | | 2018 | 1 | 2 | 3 | | 2019 | 2 | 0 | 2 | | 2020 | 0 | 4 | 4 | | 2021 | 0 | 6 | 6 | | 2022 | 0 | 6 | 6 | | 2023 | 0 | 2 | 2 | | 2024 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Infliximab" by people in Profiles.
-
Ishikawa T, Nishimura K, Okamoto N, Akamine K, Inoue N, Irabu H, Kato K, Keino H, Kojima M, Kubo H, Maruyama K, Mizuta M, Shabana K, Shimizu M, Sugita Y, Takakuwa Y, Takanashi S, Takase H, Umebayashi H, Umezawa N, Yamanishi S, Yamazaki K, Yashiro M, Yasumi T, Mori M. Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: A systematic review. Mod Rheumatol. 2024 Dec 25; 35(1):174-184.
-
Lai JM, Milner DC, Frisbie R, Puente MA. Abducens nerve palsy: a rare copresenting sign of incomplete Kawasaki Disease. J AAPOS. 2025 Feb; 29(1):104061.
-
Liu A, Xuan A, Socal M, Anderson G, Anderson KE. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019. J Manag Care Spec Pharm. 2024 Jan; 30(1):15-21.
-
White S, Morrow R, Pan I, de Zoeten EF. Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric Gastroenterologists. J Pediatr Gastroenterol Nutr. 2023 06; 76(6):701-703.
-
Kumar M, Harvey RN, Osei SK, Fatima A, Menning AZ, Akay B, Brahmamdam P, Stallion A, Novotny NM. The Evolving Effectiveness of Biologics in Avoiding Surgery in Children With Ulcerative Colitis: At what Nutritional Cost? Am Surg. 2023 Dec; 89(12):5584-5591.
-
Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2022 12 01; 75(6):724-730.
-
Constant BD, de Zoeten EF, Weinman JP, Albenberg L, Scott FI. Early Anti-Tumor-Necrosis-Factor Therapy for Crohn's Disease-Related Abdominal Abscesses and Phlegmon in Children. Dig Dis Sci. 2023 03; 68(3):877-888.
-
Kerur B, Fiedler K, Stahl M, Hyams J, Stephens M, Lu Y, Pfefferkorn M, Alkhouri R, Strople J, Kelsen J, Siebold L, Goyal A, Rosh JR, LeLeiko N, Van Limbergen J, Guerrerio AL, Maltz RM, Karam L, Crowley E, Griffiths AM, Heyman MB, Deneau M, Benkov K, Noe J, Moulton D, Pappa H, Galanko J, Snapper S, Muise AM, Kappelman MD, Benchimol EI. Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study From North America. J Pediatr Gastroenterol Nutr. 2022 07 01; 75(1):64-69.
-
Conran CA, Moreland LW. A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol. 2022 06; 64:102234.
-
Hussaini SMQ, Gupta A, Anderson KE, Ballreich JM, Nicholas LH, Alexander GC. Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019. JAMA Netw Open. 2022 03 01; 5(3):e221117.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|